Introduction
Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is an aggressive B-cell lymphoma (B-NHL). PMBCL characteristically presents as a large mediastinal tumor, frequently involving adjacent mediastinal structures and often accompanied by superior vena cava syndrome and obstruction of the upper airways (1) . PMBCL patients are predominantly female and often present with pleural and/or pericardial effusion (2) . The most frequent extrathoracic manifestations are tumors in the kidney and more rarely in the liver, spleen and pancreas, while spread to other extranodal organs is rare. The clinical presentation suggests that PMBCL may arise from specific B-cells residing in the thymic medulla (1) (3).
PMBCL reveals a typical histopathological morphology with blastic cytology and compartmentalizing alveolar fibrosis (3;4) . However, the morphology can be very (1) . Although the true incidence of MGZL in adults is not known, the disease seem to be rare, since the largest series reported so far included only 21 patients (13).
In clinical trials involving children and adolescents with PMBCL event-free survival (EFS) was achieved in about 70% of patients, a rate that is significantly lower than in other B-cell lymphomas, such as diffuse large B-cell lymphoma (DLBCL) or Burkitt Lymphoma (BL), in this age group (2) . Remarkably, in contrast to all other B-cell lymphomas PMBCL in adults has been reported to have a similar or even better outcome than in pediatric patients. This was especially the case if an anti-CD20 antibody was included, a procedure that is standard in adult aggressive B-cell lymphoma (14), but not in children and adolescents so far (15). Therefore, improving the treatment outcome in children suffering from PMBCL remains a major challenge for pediatric oncologists (16). The clinical presentation of PMBCL patients is comparable in adult and pediatric series (2) . However, the frequency of MGZL in children and adolescents has not been studied in larger series. MGZL has attracted considerable attention among pediatric oncologists, because it is possible that the outcome of PMBCL and MGZL differs. Recently, excellent progression-free survival (PFS) was reported for patients diagnosed withB-NHL in the mediastinum treated with DA-EPOCH chemotherapy (dose adjusted Etoposide, Vincristine, Doxorubicine, Cyclophosphamide, Prednisone) in combination with the anti-CD20 antibody rituximab (DA-EPOCH-R) (17). Interestingly, the outcome of PMBCL and MGZL differed dramatically, with a PFS of 100% (n=35) and 30% (n=11), respectively. The data of Dunleavy at al. suggest that PMBCL can be successfully treated with DA-R-EPOCH. However, if current diagnostic criteria are used, MGZL remains a disease with a poor outcome (17). It is worthy of note that the aforementioned trial was not randomized and did not include any children or adolescents (median age 32 years, range 19 to 52 years (13)). Detailed immunohistochemical and genetic studies of pediatric PMBCL are lacking so far. Therefore, the question whether biological differences between PMBCL in children and adults might explain the differences in outcome remains unsolved. Furthermore, it is not known whether unrecognized MGZL might be admixed within the cohorts of the previous trials for pediatric PMBCL.
If this would be the case, it might also be the cause of the relatively poor outcome. To this end, 52 patients with mediastinal tumors initially diagnosed and treated as PMBCL in the study groups for pediatric non-Hodgkin's lymphoma in Italy (AIEOP) and Germany (NHL-BFM) were identified and reanalyzed by a pathology panel using the same diagnostic criteria as in the new WHO classification and further characterized by interphase cytogenetics (1).
Design and Methods

Clinical data
Samples from 43 of 55 patients registered at the German NHL-BFM study group between December 1986 and January 2009 with the diagnosis of PMBCL were available for review. Thus, the cohort appears to be representative for the whole NHL-BFM group. The NHL-BFM group presents a population based clinical cohort for Germany. However, for patients older than 14 years (70% of all patients in the cohort 
Immunohistochemistry
The staining panel included CD20, CD79a, CD30, CD15, CD23, CD5, CD10, Pax5, Oct2, Bob1, BCL6 and MUM1. In addition Eppstein-Barr Virus (EBV) was detected using EBER in situ hybridization. Due to the retrospective nature of the study, the staining procedures and antibodies varied from patient to patient. Since material obtained from the mediastinum is usually limited, the number of immunohistochemical stainings also varied from case to case.
Fluorescence in situ hybridization (FISH)
Interphase FISH for detection of chromosomal breaks or imbalances involving the MYC (8q24), REL/BCL11A (2p16) and JAK2/PDL2 (9p24) loci was performed on available paraffin sections using probes described in supplementary Table 1 and previously published protocols (19). Gains were considered when three or four signals per probe were observed in a significant percentage of cells (10%).
Amplifications are were defined as more than four signals or the presence of a signal cloud.
Results
Pathology review
The retrospective review of 52 lymphomas by the international pathology panel revealed the diagnosis of PMBCL in 44 cases (85%), MGZL in 4 (8%) and DLBCL in 2 (4%). Two lymphomas (4%) were not classifiable due to the limited amount of material available for review and were classified as B-cell lymphoma, not otherwise Table 2 ).
The inter-observer concordance was very good. In 42 of 52 cases (81%) at least 6 of 7 observers agreed on the diagnosis after the individual microscope analysis.
However, since the study was not designed to test inter-observer reproducibility and because a very large group of observers (n=7) analyzed the specimen the Kappa value was relatively poor (Kappa = 0.35) (20). At the multi-headed microscope 11 cases were discussed. Four of these cases received the consensus diagnosis PMBCL, 4 MGZL and 2 B-cell lymphoma, not otherwise specified (Online Supplementary Table 2 ).
Immunohistochemistry and EBER in situ hybridization
The immunohistochemical profile of PMBCL and MGZL revealed only minor differences. Both entities were positive for B-cell markers such as CD20, CD79a and Pax5, and frequently expressed CD30 and CD23 ( Table 2 ). The only statistically significant difference was that BCL6 expression turned out to be more frequent in PMBCL (28/29) than MGZL (1/3, p=0.0177, Fisher's exact test). The data from the immunohistochemical analysis are summarized in Table 1 and Online Supplementary   Table 2 .
Within this large cohort the pathology panel observed some unusual features of PMBCL and MGZL. One lymphoma was negative for CD20 but otherwise showed the typical morphology and immunophenotype of PMBCL (case 36 supplementary table   2 ). The panel agreed that this lymphoma represented a rare example of a primary CD20 negative PMBCL. It is worthy of note that two cases classified as MGZL were positive for EBV encoded RNA, as detected by EBER in situ hybridization.
Nevertheless, the panel agreed that the morphological features of these lymphomas, which included sheets of blasts, and the immunophenotype, with a preserved B-cell phenotype (positive for CD20, and CD79a), did not favour the diagnosis of cHL and the lymphomas were classified as MGZL (Figure 2 ).
Interphase cytogenetics
Unfortunately, only one of the 4 MGZL were accessible for genetic studies, which did not reveal any gains in 2p, 9p or a MYC break (supplementary table 1 Table 3 outlines the clinical characteristics of the PMBCL and MGZL in the patients.
Clinical correlations
Due to the low number of MGZL in our cohort, statistical comparisons of PMBCL and MGZL are not feasible. However, there were no obvious differences between the two entities with respect to gender distribution, median age, LDH, or pleural effusions (Table 3 ). The sex ratio in PMBCL female:male was 21:23 and in MGZL 1: 3 ( Table   3 ).
The two patients with lymphomas that were re-classified by the pathology panel as 
Discussion
This study represents a large series of PMBCL and MGZL in children and adolescents analyzed so far for pathological, clinical and genetic features. In fact, no systematic series of genetic analyses of pediatric PMBCL have been published yet.
The review process involving internationally recognized experts in the field of hematopathology who reviewed all cases on individual microscopes independently of each other revealed a high inter-observer concordance. In fact, most of the pediatric lymphomas resembled morphological prototypes of PMBCL, and discussions of discordant cases (on which fewer than 6 of 7 observers agreed on the diagnosis) were primarily required for MGZL and other diagnoses. Only 4 PMBCL, reflecting 9% of all PMBCL in the cohort, required additional discussion.
PMBCL in children expressed a complete B-cell immunophenotype, including CD20
in all but one case. The expression of CD30 and CD23 in childhood PMBCL (77% and 67%, respectively) is comparable to reports in adults (>80% and 70%, respectively) (1). Furthermore, the frequency of gains/amplifications in 2p16 (REL/BCL11A, 41%) and 9p24 (JAK2/PDL2, 59%) was similar to the findings reported for adult PMBCL (1). We conclude that the morphology, genetics and immunophenotype as far as analyzed herein of PMBCL is similar between children and adolescents on the one side and adults on the other hand. This study did not find any indication of biological differences between childhood and adult PMBCL, as had been speculated in previous publications discussing therapeutical aspects of pediatric PMBCL (16). However, more a comprehensive molecular genetic profiling will be needed in future studies to fully whether or not molecular differences exists between both age groups. Interestingly, lymphomas resembling PMBCL morphologically and immunophenotypically might harbor chromosomal translocations involving the MYC locus as we have shown here in one case. However, the fact that our study identified four MGZL in 52 PMBCL cases strongly suggests the absolute and relative rarity of MGZL in children.
In recent trials treating children and adolescents suffering from PMBCL, an EFS of approximately 70% was achieved (14). Thus PMBCL remains an entity with a poorer prognosis than other aggressive B-NHL in children (2;16). Compared to pediatric regimens, adult protocols include higher cumulative doses of doxorubicin, etoposide, alkylating agents and bleomycin, but little or no methotrexate(15;16;22). Furthermore, radiation therapy was performed in addition to chemotherapy in most adult series, although the role of radiation remains a matter of debate (14). Data from the National Cancer Institute study using DA-EPOCH-R suggest that patients with PMBCL benefit dramatically from the addition of rituximab to chemotherapy protocols for PMBCL (17). After addition of rituximab to DA-EPOCH chemotherapy, the progression-free survival increased from 67% to 91% in subsequently treated patients (17). Although these have been the best clinical results reported so far, the data have several limitations, mainly due to the fact that study was performed in a single institution.
Data on pediatric PMBCL patients treated with DA-EPOCH + rituximab are lacking so far, and other chemotherapy protocols have also proven to be effective (14).
However, our study might be helpful for designing future therapeutic approaches for PMBCL in children. Our data show similar morphological, immunohistochemical or genetic features in PMBCL in children and adults, although we can not rule out biological differences that might only be detectable by molecular techniques such as gene expression or genetic profiling. The only clinically relevant difference between childhood and adult PMBCL seems to be the gender distribution, with a female predominance in adulthood, while male and female patients are affected equally in childhood. However, lacking any proof of biological differences, we suggest that the differences in therapeutic outcome between the two age groups can most likely be attributed to differences in the treatment protocols.
It should be noted that within the patient cohort treated with DA-EPOCH-R, the pPFS at 4-years median follow-up was 33% in MGZL compared to 100% for PMBCL (17).
Thus even under multi-agent chemotherapy including rituximab MGZL remains a disease with a very unfavorable diagnosis. However, since MGZL is a rare disease in both adults and children, clinical data on the outcome of MGZL are scarce.
Nevertheless, the results of our study identified only a very small number of MGZL in past trials of pediatric PMBCL. Indeed, the results of the reclassification and confirmation of diagnosis by the international pathology panel using current diagnostic criteria emphasize that the unsatisfying therapeutic results in pediatric PMBCL are unlikely to be due to a contamination of the past cohorts by MGZL.
In summary, this large retrospective study did not reveal any morphological, immunophenotypical, or genetic differences between PMBCL in children compared with previous studies in adult patients. Furthermore, we have shown that MGZL exist in children but are rare in the cohorts of previous trials for PMBCL. The lack of evidence of biological differences between adult and pediatric PMBCL and the rarity of MGZL in childhood suggest that differences in outcome between children and adults suffering from PMBCL are most likely attributable to differences in the therapeutic protocols. These findings might help to design new therapeutic strategies for PMBCL in children.
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